MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

Phase 4
Completed
Conditions
Constipation
First Posted Date
2006-04-27
Last Posted Date
2013-02-07
Lead Sponsor
Braintree Laboratories
Target Recruit Count
25
Registration Number
NCT00319670

MOVIPREP® Versus PICOLAX® Pilot Study

First Posted Date
2006-04-10
Last Posted Date
2007-12-17
Lead Sponsor
Norgine
Target Recruit Count
65
Registration Number
NCT00312481
Locations
🇬🇧

John Radcliffe Hospital, Department of Gastroenterology, Endoscopy Unit, Headley Way, Headington, Oxford, Oxfordshire, United Kingdom

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

Phase 1
Completed
Conditions
Chronic Myeloid Leukemia
Interventions
First Posted Date
2006-03-16
Last Posted Date
2015-11-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
76
Registration Number
NCT00303290
Locations
🇺🇸

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication

Phase 3
Terminated
Conditions
Chronic Hepatitis C
HIV Infections
First Posted Date
2006-02-27
Last Posted Date
2007-04-23
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
100
Registration Number
NCT00296972
Locations
🇨🇦

University Health Network, Toronto General Hospital, Toronto, Ontario, Canada

Study of Long-term Use of Forlax® in Elderly Patients With Chronic Constipation

Phase 4
Completed
Conditions
Constipation
First Posted Date
2006-01-13
Last Posted Date
2019-07-26
Lead Sponsor
Ipsen
Target Recruit Count
246
Registration Number
NCT00276354
Locations
🇫🇷

19 rue Jules Guesde, Abscon, France

🇫🇷

89 avenue de Niort, Beauvoir Sur Niort, France

🇫🇷

39, avenue de France, Blois, France

and more 142 locations

To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

Phase 3
Completed
Conditions
Chronic Constipation
Interventions
First Posted Date
2005-11-18
Last Posted Date
2020-04-24
Lead Sponsor
Ipsen
Target Recruit Count
88
Registration Number
NCT00255372
Locations
🇹🇭

Ramathibodi Hospital, Mahidol University,, Bangkok, Thailand

🇹🇭

Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Phase 4
Completed
Conditions
Hepatitis C
Interventions
First Posted Date
2005-09-21
Last Posted Date
2012-02-14
Lead Sponsor
Brooke Army Medical Center
Target Recruit Count
610
Registration Number
NCT00207363
Locations
🇺🇸

Brooke Army Medical Center, Ft. Sam Houston, Texas, United States

Study of Long-term Peg Intron vs. Colchicine in Non-responders.

Phase 4
Completed
Conditions
Hepatitis C Virus
Advanced Fibrosis
Cirrhosis
Interventions
First Posted Date
2005-09-16
Last Posted Date
2017-07-11
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
549
Registration Number
NCT00179413
Locations
🇺🇸

Southern Clinical Research Consultants, Hollywood, Florida, United States

🇺🇸

Lahey Clinic, Burlington, Massachusetts, United States

🇺🇸

Fallon Clinic, Worcester, Massachusetts, United States

and more 45 locations

ADI-PEG in Patients With Metastatic Melanoma

Phase 1
Completed
Conditions
Melanoma
Neoplasm Metastasis
First Posted Date
2002-01-25
Last Posted Date
2015-03-25
Lead Sponsor
FDA Office of Orphan Products Development
Target Recruit Count
15
Registration Number
NCT00029900
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath